$heff's $tation of $tocks & $olid DD

[ash111]

SPHS liking the SS,the low cap,the market potential.the balance sheet still solid.already Funded to P2 Localized prostate cancer(huge mrkt,data will be released in early 2016), and P3 BPH(huge mrkt as well,positive P3 data out) results..
Strong Mgmt, Good IP and patent longevity. Drug not difficult or overly expensive to produce.

Institutional & Mutual Fund was not able to buy shares when this was trading under 1 before the positive P3 data.the volume jumped to sky the days after,and average buy price was way over $3.

Treatment has “blockbuster” potential – meaning annual sales of more than $1 billion". http://www.pharmalive.com/sophiriss-prostate-drug-meets-main-goal-in-late-stage-study/

the competitor is trading up to 4 times SPHS's cap on negative Cash flow. $6-$7,(or about $100m cap) is a very reasonable short term PT after reporting positive P3 DATA.thats why im holding this one.
"PRX302 is the only single-administration investigational treatment for BPH that has demonstrated a statistically significant improvement in symptoms of BPH, is well-tolerated, and has a favorable safety profile.

New presentation (Website) out lat week.catalyst pgs. 32 http://files.shareholder.com/downloads/AMDA-1OKDCO/730922784x0x862144/EF1C62FD-D358-4E10-A4BD-57ECC35316A9/Sophiris_Bio_Inc_November_2015.pdf